Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?

Atherosclerotic cardiovascular diseases are the leading cause of adverse outcomes in patients with type 2 diabetes, and all new anti-diabetic agents are mandated to undergo cardiovascular outcome trials (CVOTs). Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are incretin mimetics that reduce b...

Descripción completa

Detalles Bibliográficos
Autores principales: Melo, Miguel, Gavina, Cristina, Silva-Nunes, José, Andrade, Luís, Carvalho, Davide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317280/
https://www.ncbi.nlm.nih.gov/pubmed/34315528
http://dx.doi.org/10.1186/s13098-021-00698-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317280/
https://www.ncbi.nlm.nih.gov/pubmed/34315528
http://dx.doi.org/10.1186/s13098-021-00698-5

Ejemplares similares